AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00005988
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00544414
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05845996
Drug: SAR441344
RxNorm normalized name: Immunoglobulin G1 (272-arginine,325-alanine), anti-(human CD40 ligand) (human-mus musculus monoclonal SAR441344 gamma1-chain), disulfide with human-mus musculus monoclonal SAR441344 kappa-chain, dimer
DrugBank: Frexalimab (DB18926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for intravenous/subcutaneous injection
Trial: NCT02207231
Drug: Guselkumab 100 mg
RxNorm normalized name: guselkumab 100 MG/ML
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg by subcutaneous injection at Weeks 0, 4 and q8w thereafter through Week 252 (Group 1). 100 mg by subcutaneous injection at Weeks 16, 20 and q8w thereafter through Week 252 (Group II). 100 mg by subcutaneous injection at Week 52 and q8w thereafter through Week 252 (Group III).
Trial: NCT02207231
Drug: Placebo for guselkumab
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous injections to maintain the blind.
Trial: NCT00005988
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01869309
Drug: Prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will discontinue ticagrelor treatment and start 10 mg prasugrel daily while continuing 81 mg of aspirin daily.
Trial: NCT01869309
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be given 180 mg of Ticagrelor followed by 90 mg twice a day while continuing 81 mg of aspirin daily).
Trial: NCT02207231
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 47.
Trial: NCT02458638
Drug: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be given as IV infusion over 60 minutes on Day 1 of Cycle 1, then over 30 minutes (as tolerated) on Day 1 of each subsequent 3-week cycle.
Trial: NCT00665041
Drug: Quinagolide
RxNorm normalized name: quinagolide
DrugBank: Quinagolide (DB09097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • Quinagolide 200 μg/day (dose titration from 50 μg/day to 100 μg/day to 200 μg/day), oral. Quinagolida tablets, 50 mcg.~placebo, oral.
Trial: NCT01208480
Drug: Avastin, docetaxel, carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Avastin, docetaxel, carboplatin
Trial: NCT00485303
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Abiraterone acetate oral tablets 250 milligram (mg) each will be administered at a total dose of 1000 mg until documented disease progression or unacceptable toxicity.
Trial: NCT00485303
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone/Prednisolone 5 mg tablet will be taken orally twice daily.
Trial: NCT00128427
Drug: Colchicine (for 1 month)
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04424901
Drug: Dipyridamole Tablets
RxNorm normalized name: Dipyridamole Tablets
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily dose while hospitalized up to 9 days
Trial: NCT00287118
Drug: Efalizumab
RxNorm normalized name: Efalizumab
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects will receive a conditioning dose of 0.7 milligram per kilogram (mg/kg) efalizumab subcutaneously on study Day 0 followed by 1.0 mg/kg efalizumab subcutaneously once a week for 23 weeks.
Trial: NCT01785836
Drug: Dapsone Formulation A
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone Formulation A applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
Trial: NCT01785836
Drug: Dapsone Formulation B
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone Formulation B applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
Trial: NCT03805269
Drug: TAP block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAP block: local anesthetics infiltration at trans abdominis plane
Trial: NCT01785836
Drug: Dapsone Formulation C
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone Formulation C applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
Trial: NCT01785836
Drug: Dapsone 5% Gel
RxNorm normalized name: DAPSONE 5% GEL,TOP
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dapsone 5% gel (ACZONE®) applied twice daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
Trial: NCT02349165
Drug: Isotonic riboflavin
RxNorm normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After epithelium removal, isotonic riboflavin was instilled during 30 minutes before ultraviolet-A irradiation
Trial: NCT01631864
Drug: amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: amlodipine was provided as 5 mg tablets.
Trial: NCT01398384
Drug: MI size at 48-72 hours
RxNorm normalized name: Feng Mi
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gas
Trial: NCT01038570
Drug: Physiological serum (Sodium chloride)
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride 0.9 % (0.3 ml) in each nostril
Trial: NCT00262600
Drug: warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once a day
Trial: NCT00262600
Drug: Dabigatran dose 1
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily
Trial: NCT00262600
Drug: Dabigatran dose 2
DrugBank: Dabigatran (DB14726)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice a day
Trial: NCT03111433
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: multiple dose insulin injection therapy
Trial: NCT02134756
Drug: NutraStem Active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00098488
Drug: tanespimycin
RxNorm normalized name: Tanespimycin
DrugBank: Tanespimycin (DB05134)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00310518
Drug: ARQ 501
RxNorm normalized name: ARQ 092
DrugBank: Miransertib (DB14982)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00583700
Drug: Pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg, 3 times daily for 7 months, beginning immediately after radiation therapy.
Trial: NCT00583700
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (Over-the-counter) 400 I.U. once daily
Trial: NCT01580878
Drug: Butenafine Hydrochloride Cream, 1%
DrugBank: Butenafine (DB01091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Butenafine Hydrochloride Cream, 1% applied twice daily for 7 consecutive days
Trial: NCT01580878
Drug: Butenafine Vehicle
DrugBank: Butenafine (DB01091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Butenafine Vehicle applied twice daily for 7 consecutive days.
Trial: NCT00452569
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral thalidomide (100mg or 200mg or 400 mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 + 36 days (12 cycles of 28 +/- 3 days).
Trial: NCT00452569
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: High dose oral dexamethasone will be administered at a dose of 40mg/day on days 1-4, 9-12 and 17-20 of each 28-day cycle for cycles 1-4. Beginning with cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg/day on days 1-4 of each 28-day cycle. Dexamethasone will be administered until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
Trial: NCT02701634
Drug: ENTO
RxNorm normalized name: Mentol
DrugBank: Pentobarbital (DB00312)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets administered orally
Trial: NCT01226056
Drug: RAD001 in combination with sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phase I / Dose escalation: during the first cycle RAD001 (2.5-10 mg/day) will be administered alone, once a day, on days 1-14 to allow PK-profiling of the drug. From day 15 sorafenib administration (400-800 mg/day) twice a day will be added.~The cycle 1 will last 6 weeks, subsequent cycles will last 4 weeks (the 2 drugs administered in combination from day 1 to day 28).~Phase II: The drugs will be administered at the Recommended Dose and each treatment cycle will last 4 weeks.
Trial: NCT02655237
Drug: Relugolix
RxNorm normalized name: Relugolix
DrugBank: Relugolix (DB11853)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Relugolix tablets
Trial: NCT02655237
Drug: Relugolix Placebo
DrugBank: Relugolix (DB11853)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Relugolix placebo-matching tablets
Trial: NCT02655237
Drug: Leuprorelin
RxNorm normalized name: Leuprorelin
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leuprorelin injection
Trial: NCT01572792
Drug: Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) high dose, twice per day
Trial: NCT01572792
Drug: Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) low dose, twice per day
Trial: NCT02222428
Drug: BI 54903 XX
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02222428
Drug: BI 1744 CL
RxNorm normalized name: hydroxypropyl bis-hydroxyethyldimonium chloride
DrugBank: Propyl acetate (DB01670)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01572792
Drug: Aclidinium bromide
RxNorm normalized name: Aclidinium Bromide
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inhaled Aclidinium bromide 400 μg, twice per day
Trial: NCT01572792
Drug: Formoterol Fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inhaled Formoterol Fumarate 12 μg, twice per day
Trial: NCT04126811
Drug: Apatinib Mesylate, Pirarubicin, Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Apatinib 500mg, orally, once a day. One cycle every 4 weeks. Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks.
Trial: NCT04126811
Drug: Apatinib Mesylate
RxNorm normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib 500mg, orally, once a day. One cycle every 4 weeks.
Trial: NCT04126811
Drug: Pirarubicin, Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pirarubicin 75mg/m2 D1, intravenous infusion for 1-2 hours; every 4 weeks. Ifosfamide 2g/m2/d D1-D5, intravenously for 4-6 hours, 1 cycle every 4 weeks
Trial: NCT00437242
Drug: Odiparcil
RxNorm normalized name: Odiparcil
DrugBank: Odiparcil (DB06609)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00464165
Drug: rimonabant
RxNorm normalized name: Rimonabant
DrugBank: Rimonabant (DB06155)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT02280629
Drug: Mesalamine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LT-02 PLACEBO twice daily AND mesalamine 500mg three-times daily
Trial: NCT00561730
Drug: Pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observational, non-interventional study (NIS). The physician decided about dosage according to individual needs (20 or 40 mg pantoprazole, once daily).
Trial: NCT00376220
Drug: Riluzole
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initially dispensed 50 mg capsules to take twice a day (BID). At two weeks, increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules in the morning (qAM), two capsules in the evening (qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as Montgomery Asberg Depression Rating Scale (MADRS) \< 12) the dose will not be increased further unless clinical symptoms recur.
Trial: NCT03399526
Drug: Mapracorat (ZK 245186, BAY 86-5319)
RxNorm normalized name: Mapracorat
DrugBank: Mapracorat (DB12041)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% (1 mg/g) of the active ingredient mapracorat plus excipients as ointment
Trial: NCT03399526
Drug: Prednicarbate 0.25% ointment
DrugBank: Prednicarbate (DB01130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% (2.5 mg/g) of the active ingredient prednicarbate as ointment
Trial: NCT03399526
Drug: Clobetasol 0.05% ointment
DrugBank: Clobetasol (DB11750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% (0.5 mg/g) of the active ingredient clobetasol as ointment
Trial: NCT03399526
Drug: Calcipotriene 0.005%/Betamethasone dipropionate 0.05% ointment
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.005% (0.05 mg/g) of the active ingredient calcipotriene/0.05% (0.5 mg/g) of the active ingredient betamethasone dipropionate as ointment
Trial: NCT00269048
Drug: SB-480848
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB-480848
Trial: NCT00475332
Drug: Iodine I -01 Tositumomab (Bexxar)
DrugBank: Tositumomab (DB00081)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated in two dosing phases, each phase includes two infusions. The first phase, termed dosimetric dose, involves an intravenous administration of 450 mg unlabeled tositumomab followed by an intravenous administration of 5 mCi (0.18 GBq) of I-131 tositumomab for the purpose of determining the rate of whole body clearance of radioactivity (residence time) so that the administered activity (mCi or GBq) to deliver a 75 cGy (or 65 cGy for patients with baseline platelet count from 100,000 to 149,999/mm\^3) total body radiation dose can be calculated.
Trial: NCT00689936
Drug: Lenalidomide and low-dose dexamethasone
RxNorm normalized name: ethinyl estradiol
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg 20mg, or 25 mg capsules, given either days 1-21 of each 28 day cycles or given every other day for 21 days until documentation of PD.~Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle up to disease progression
Trial: NCT00689936
Drug: Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg, 20 mg or 25 mg capsules given on days 1-21 of each 28 day cycle or every other day for 21 days for 18 cycles.~Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle for 18 cycles
Trial: NCT00689936
Drug: Melphalan, Prednisone and Thalidomide
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan - oral, 2mg tablets dosed at either 0.25mg/kg, 0.125 mg/kg, 0.20mg/kg or 0.10mg/kg on days 1-4 of each 42 day cycle up to 12 cycles Prednisone - oral, 5mg, 10mg, 20 mg and 50 mg tablets dosed at 2mg/kg daily days 1-4 of each 42 day cycle for up to 12 cycles Thalidomide - oral, 50mg, 100mg and 200 mg capsules dosed at either 100mg or 200 mg daily on days 1-41 of each 42 day cycle for up to 12 cycles
Trial: NCT01375101
Drug: Quercetin
RxNorm normalized name: Quercetin
DrugBank: Quercetin (DB04216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient is directed to digest quercetin hydrate capsule two times a day,until one mouth
Trial: NCT00084630
Drug: imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given orally
Trial: NCT02543411
Drug: Lidocaine 1%
RxNorm normalized name: LIDOCAINE 1% LOTION
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous administration as bolus of lidocaine 1.5 mg/kg before sedation and infusion of lidocaine 2 mg/kg/hr during sedation.~Sedation with fentanyl and propofol
Trial: NCT02587416
Drug: Gemcabene 300 mg
RxNorm normalized name: Gemcabene
DrugBank: Gemcabene (DB05123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1x300 mg gemcabene tablets orally once daily (QD) for 11 days
Trial: NCT02587416
Drug: Gemcabene 900 mg
RxNorm normalized name: Gemcabene
DrugBank: Gemcabene (DB05123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3x300 mg Gemcabene tablets orally once daily (QD) for 11 days
Trial: NCT02587416
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2x40 mg Atorvastatin tablets orally once daily (QD)
Trial: NCT04035798
Drug: Memantine or placebo
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BP-II patients who are older than 40 years old will be recruited, and allocate them to add-on memantine or placebo plus standard valproic acid treatment in a 1: 1 ratio. The participants will receive memantine 5mg/day or placebo treatment for 12 weeks.
Trial: NCT02856178
Drug: Caspofungin
RxNorm normalized name: Caspofungin
DrugBank: Caspofungin (DB00520)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Caspofungin treatment starting during chemotherapy for concomitant prophylaxis of fungal infection. Loading dose 70 mg q.d., maintenance doses 50 mg q.d.
Trial: NCT00726869
Drug: Elotuzumab (HuLuc63)
RxNorm normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cohort 1 - 2.5 mg/kg elotuzumab IV with bortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8; Cohort 2 - 5.0 mg/kg elotuzumab IV with bortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8; Cohort 3 - 10.0 mg/kg elotuzumab IV withbortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8; and Cohort 4 - 20.0 mg/kg elotuzumab IV with bortezomib on Days 1 \& 11, with only Bortezomib IV on Days 4 \& 8.
Trial: NCT02124525
Drug: N-acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine 3000mg a day for 12 weeks versus Placebo for 12 weeks
Trial: NCT01211470
Drug: Daptomycin
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active Comparator: Daptomycin.
Trial: NCT01211470
Drug: PMX-30063-investigational drug
RxNorm normalized name: PMX-205
DrugBank: PMX-205 (DB17938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental: PMX-30063
Trial: NCT00880997
Drug: Doxazosin
RxNorm normalized name: Doxazosin
DrugBank: Doxazosin (DB00590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication induction occurred at a rate of 2mg/week until 8mg/day target dose was achieved as follows:~1. Dox-Fast Group: Defined as participants reaching the target dose after a 4-week titration period. Participants were stabilized on doxazosin or placebo over weeks 4-13 (for Dox-Fast group)~2. Dox-Slow Group: Defined as participants reaching the target dose after an 8-week titration period. Participants were stabilized on doxazosin or placebo over weeks 8-13 (for Dox-Slow group)~Both doxazosin groups will be tapered off doxazosin or placebo over study weeks 14-17.
Trial: NCT01122771
Drug: Liposomal amphotericin B
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ambisome i.v. 5mg on days 1, 3 and 5
Trial: NCT01122771
Drug: liposomal amphotericin B + miltefosine
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ambisome 5mg single dose iv Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10)
Trial: NCT01640496
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3000 IU Vitamin D3 tablets (Cholecalciferol) will be used. 28 pills per bottle. Subjects will be given 2 bottles to be taken for the duration of this study.
Trial: NCT01138735
Drug: adapalene/benzoyl peroxide
RxNorm normalized name: ADAPALENE/BENZOYL PEROXIDE
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily topical application for 12 weeks